uniQure (NASDAQ:QURE) Insider Sells $30,912.72 in Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the transaction, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. This trade represents a 2.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

uniQure Trading Up 34.0%

QURE opened at $14.27 on Monday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The stock’s 50 day moving average price is $22.04 and its 200-day moving average price is $29.63. uniQure N.V. has a one year low of $7.76 and a one year high of $71.50. The stock has a market cap of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. On average, equities analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Institutional Trading of uniQure

A number of hedge funds have recently added to or reduced their stakes in QURE. Private Trust Co. NA bought a new position in uniQure during the 3rd quarter worth about $28,000. Torren Management LLC purchased a new position in uniQure during the 4th quarter valued at about $28,000. Jones Financial Companies Lllp raised its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of uniQure in the 4th quarter valued at about $48,000. Finally, Smartleaf Asset Management LLC purchased a new stake in shares of uniQure in the 4th quarter worth approximately $48,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

QURE has been the subject of a number of recent analyst reports. Barclays started coverage on shares of uniQure in a research note on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Sanford C. Bernstein downgraded shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 target price (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $15.00 price target (down from $60.00) on shares of uniQure in a research note on Tuesday, March 3rd. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $34.33.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.